However, not all patients with ER+ breast cancer benefit from endocrine treatment: 40–50% relapse after adjuvant endocrine therapy [1] and 50–70% show a clinical response after neoadjuvant endocrine therapy (NET) [1–3]. The gene discussed is ESR1; the disease is breast carcinoma.